Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:
|Active Ingredient:||Dapagliflozin propanediol monohydrate 12.3mg equivalent to dapaglifozin 10mg|
|Dosage Form:||Film coated tablet|
|New Zealand Sponsor:||AstraZeneca Limited|
|Manufacturers:||Bristol-Myers Squibb Manufacturing Company Unlimited Company, Humacao, Puerto Rico
AstraZeneca Pharmaceuticals LP, Indiana, United States of America
Dated this 4th day of September 2023.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).